Skip to main content
Microbiology Resource Announcements logoLink to Microbiology Resource Announcements
. 2019 Feb 7;8(6):e01524-18. doi: 10.1128/MRA.01524-18

First Draft Genome Sequence of Leishmania (Viannia) lainsoni Strain 216-34, Isolated from a Peruvian Clinical Case

Wuling Lin a,c, Dhwani Batra b, Vidhya Narayanan a,c, Lori A Rowe b, Mili Sheth b, Yueli Zheng a,d, Phalasy Juieng b, Vladimir Loparev b, Marcos de Almeida a,
Editor: Vincent Brunoe
PMCID: PMC6368655  PMID: 30746520

We present here the first draft genome sequence of Leishmania (Viannia) lainsoni strain 216-34, sequenced using PacBio and MiSeq platforms. PacBio contigs were generated from de novo assemblies using CANU version 1.6 and polished using Illumina reads.

ABSTRACT

We present here the first draft genome sequence of Leishmania (Viannia) lainsoni strain 216-34, sequenced using PacBio and MiSeq platforms. PacBio contigs were generated from de novo assemblies using CANU version 1.6 and polished using Illumina reads.

ANNOUNCEMENT

In South and Central America, cutaneous leishmaniasis (CL) is caused by several Leishmania species in the Leishmania and Viannia subgenera (1, 2). Patients infected with some Leishmania (Viannia) strains of L. (V.) braziliensis, L. (V.) guyanensis, and L. (V.) panamensis can also develop mucocutaneous leishmaniasis (MCL), a mucosa-destructive sequela affecting the naso-oropharyngeal and laryngeal tracts (3). Other species in the Viannia subgenus, such as L. (V.) lainsoni and L. (V.) peruviana, are associated only with CL. Treatment is recommended for most cases of CL. However, the drugs typically used for treating CL are associated with several adverse side effects. In addition, the choice of therapeutic agents and their efficacy vary by clinical characteristics and parasite-specific factors (3 5). Therefore, DNA-based diagnostic tests that allow specific identification of infecting parasite species are critical for appropriate clinical management, including decisions regarding which treatment is indicated and how to monitor for relapse and sequelae.

As a part of our efforts to improve the quality of species-specific diagnostics for leishmaniasis, we present here the first draft genome sequence of L. (V.) lainsoni, that of strain 216-34, derived from a parasite isolated in our laboratory from a clinical case from Peru in 2016. Parasites grown in RPMI 1640 axenic medium (Life Technologies, CA) were initially identified on the basis of morphological analysis (6). Later, the species identity of L. (V.) lainsoni was confirmed using multilocus sequence analysis (MLSA) targeting glucose-6-phosphate dehydrogenase (G6PDH), isocitrate dehydrogenase (ICD), malate dehydrogenase (MDH), and mannose-6-phosphate isomerase (MPI) Leishmania sp. enzyme-coding genes. The sequencing data, generated on an ABI 3130xl DNA analyzer (Applied Biosystems, CA), were compared with the NCBI nucleotide database using the BLASTn algorithm (https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch).

MiSeq and PacBio libraries were prepared with genomic DNA purified using the MagAttract high-molecular-weight (HMW) DNA kit (Qiagen, MD). For the short reads, libraries were prepared with NEBNext Ultra library prep reagents (New England BioLabs, MA), barcoded with indices produced at the CDC Biotechnology Core Facility, and sequenced using a MiSeq 2 × 250-cycle sequencing kit (Illumina, CA). Sequence reads were filtered for read quality, base called, and demultiplexed using bcl2fastq (version 2.19). Long-read sequencing data were obtained from a 20-kb DNA library and prepared using standard PacBio 20-kb library protocols (Pacific Biosciences, CA). The library was size selected with the BluePippin system (Sage Science, MA), bound to polymerase using the DNA/polymerase binding kit P6v2, loaded onto 6 single-molecule real-time (SMRT) cells, and sequenced with C4v2 chemistry for 360-min movies on the RS II instrument (Pacific Biosciences, CA).

The reads (246,178 reads; mean read length, 12,377 bp) from the RS II instrument were filtered and de novo assembled using Canu version 1.6 (7) with default parameters. Non-Leishmania contigs identified using the NCBI-BLASTn algorithm were removed, and the remaining contigs were polished and corrected using unicycler_polish (Unicycler package version 4.4) (8) with the 26,942,306 Illumina reads. The L. (V.) lainsoni genome assembly comprises 140 contigs covering 34,156,530 bp, with an L50 value of 17, N50 value of 638,860 bp, G+C content of 57.83%, and average read coverage of 75×.

The first draft genome sequence of L. (V.) lainsoni presented here is an important resource for diagnostic applications and research on the Leishmania genus.

Data availability.

The draft genome contigs of L. (V.) lainsoni 216-34 have been deposited in GenBank under accession number RAIA00000000 and in the SRA under accession numbers SRR7883038, SRR7883039, SRR7883040, and SRR8179821 (BioProject number PRJNA484340).

ACKNOWLEDGMENT

This work was made possible through support from CDC’s Office of Advanced Molecular Detection (OAMD).

REFERENCES

  • 1.Herwaldt BL. 1999. Leishmaniasis. Lancet 354:1191–1199. doi: 10.1016/S0140-6736(98)10178-2. [DOI] [PubMed] [Google Scholar]
  • 2.Van der Auwera G, Dujardin JC. 2015. Species typing in dermal leishmaniasis. Clin Microbiol Rev 28:265–294. doi: 10.1128/CMR.00104-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, Carvalho E, Ephros M, Jeronimo S, Magill A. 2017. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Am J Trop Med Hyg 96:24–45. doi: 10.4269/ajtmh.16-84256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliveira RV, Marzochi MC, Andrade CA. 2011. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop 118:87–96. doi: 10.1016/j.actatropica.2011.02.007. [DOI] [PubMed] [Google Scholar]
  • 5.Copeland NK, Aronson NE. 2015. Leishmaniasis: treatment updates and clinical practice guidelines review. Curr Opin Infect Dis 28:426–437. doi: 10.1097/QCO.0000000000000194. [DOI] [PubMed] [Google Scholar]
  • 6.Silveira FT, Shaw JJ, Braga RR, Ishikawa E. 1987. Dermal leishmaniasis in the Amazon region of Brazil: Leishmania (Viannaia) [sic] lainsoni sp.n., a new parasite from the State of Pará. Mem Inst Oswaldo Cruz 82:289–291. [DOI] [PubMed] [Google Scholar]
  • 7.Koren S, Walenz BP, Berlin K, Miller JR, Bergman NH, Phillippy AM. 2017. Canu: scalable and accurate long-read assembly via adaptive k-mer weighting and repeat separation. Genome Res 27:722–736. doi: 10.1101/gr.215087.116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Wick RR, Judd LM, Gorrie CL, Holt KE. 2017. Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. PLoS Comput Biol 13:e1005595. doi: 10.1371/journal.pcbi.1005595. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The draft genome contigs of L. (V.) lainsoni 216-34 have been deposited in GenBank under accession number RAIA00000000 and in the SRA under accession numbers SRR7883038, SRR7883039, SRR7883040, and SRR8179821 (BioProject number PRJNA484340).


Articles from Microbiology Resource Announcements are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES